CIK 0001828522
EFTR eFFECTOR Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Feb 21, 2024.
In brief
eFFECTOR Therapeutics, Inc. (EFTR) has 7 SEC Form 4 filings on file from 6 insiders, the latest filed on Feb 21, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at EFTR. The newest: Sr One Capital Management, LLC (10% owner) sold $369k of stock on Nov 27, 2023, filed Nov 29, 2023, scored 32 (weak).
Last 90 days
Signals
Open-market buys and sells at eFFECTOR Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 32Weak | Sr One Capital Management, LLC owner sell | $369k 609,163 shares | -13% | - |
Transactions
Every row filed, 8 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 19, 2024 | Elizabeth Bhatt director | AGrant or award Stock Option (Right to Buy)derivative | +2,000 | $0.00 | $0 | 2,000 | Feb 21, 2024 |
| Feb 19, 2024 | Michael Byrnes Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Feb 21, 2024 |
| Feb 19, 2024 | Christopher B Ehrlich director | AGrant or award Stock Option (Right to Buy)derivative | +2,000 | $0.00 | $0 | 2,000 | Feb 21, 2024 |
| Feb 19, 2024 | Brian M. Gallagher Jr. director | AGrant or award Stock Option (Right to Buy)derivative | +2,000 | $0.00 | $0 | 2,000 | Feb 21, 2024 |
| Nov 27, 2023 | Sr One Capital Management, LLC owner | SOpen-market sale Common Stockindirect: See Note 2 | -430,578 | $0.61 | $261k | 4,391,536 | Nov 29, 2023 |
| Nov 27, 2023 | Sr One Capital Management, LLC owner | SOpen-market sale Common Stockindirect: See Note 3 | -178,585 | $0.61 | $108k | 1,821,415 | Nov 29, 2023 |
| Nov 15, 2023 | Michael Byrnes Chief Financial Officer | AGrant or award Common Stock | +4,524 | $0.50 | $2,250 | 43,271 | Nov 16, 2023 |
| Nov 15, 2023 | Stephen T Worland Chief Executive Officer | AGrant or award Common Stock | +5,979 | $0.50 | $2,973 | 267,204 | Nov 16, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Elizabeth Bhattcoo, president, officer, director
- Michael ByrnesChief Financial Officer
- Christopher B Ehrlichceo, chair, officer, director
- Brian M. Gallagher Jr.director
- Sr One Capital Management, LLCowner
- Stephen T WorlandChief Executive Officer
Questions about EFTR
Answered from the filings on this page, as of the latest one.
Are insiders buying EFTR?
No. In the last 90 days no insider at eFFECTOR Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade EFTR on the open market?
Sr One Capital Management, LLC (10% owner) sold $369k of EFTR on Nov 27, 2023 and filed the Form 4 on Nov 29, 2023. InsiderTell scored 32 (weak).
How many insiders file Form 4 at eFFECTOR Therapeutics, Inc.?
6 people have filed a Form 4 at eFFECTOR Therapeutics, Inc., among them Elizabeth Bhatt (COO, president and director), Michael Byrnes (Chief Financial Officer), Christopher B Ehrlich (CEO, chair and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.